Discovery and Structural Characterization of a Phospholamban-Binding Cyclic Peptide and Design of Novel Inhibitors of Phospholamban

Chemical Biology and Drug Design

Volumn 81, Issue 4, 2013, Pages 463-473

  Tilgmann, Carola ^a   Pollesello, Piero ^a   Ovaska, Martti ^a   Kaivola, Juha ^a   Pystynen, Jarmo ^a   Tiainen, Eija ^a   Yliperttula, Marjo ^b   Annila, Arto ^b   Levijoki, Jouko ^a  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Calcium uptake; Cardiac contraction relaxation cycle; Cardiomyocytes; Drug discovery; Heart disease; Pharmacophore; Sarcoplasmic reticulum

Indexed keywords

ALANINE; CYCLOPEPTIDE; PHOSPHOLAMBAN; PROTEIN INHIBITOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HEART FAILURE; HUMAN; NONHUMAN; PEPTIDE LIBRARY; PHAGE DISPLAY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; SARCOPLASMIC RETICULUM; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HEART; HUMANS; MODELS, MOLECULAR; MYOCARDIUM; PEPTIDE LIBRARY; PEPTIDES, CYCLIC; PROTEIN BINDING; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875679251     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01409.x     Document Type: Article

References (53)

1. Periasamy M., Bhupathy P., Babu G.J. (2008) Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology. Cardiovasc Res;77:265-273.
2. Periasamy M., Huke S. (2001) SERCA pump level is a critical determinant of Ca(2+)homeostasis and cardiac contractility. J Mol Cell Cardiol;33:1053-1063.
3. Li L., Chu G., Kranias E.G., Bers D.M. (1998) Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am J Physiol;274:H1335-H1347.
4. Hasenfuss G., Pieske B. (2002) Calcium cycling in congestive heart failure. J Mol Cell Cardiol;34:951-969.
5. Tomaselli G.F., Marban E. (1999) Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res;42:270-283.
6. Schmidt A.G., Zhai J., Carr A.N., Gerst M.J., Lorenz J.N., Pollesello P., Annila A., Hoit B.D., Kranias E.G. (2002) Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure. Cardiovasc Res;56:248-259.
7. Vangheluwe P., Tjwa M., Van Den Bergh A., Louch W.E., Beullens M., Dode L., Carmeliet P., Kranias E., Herijgers P., Sipido K.R., Raeymaekers L., Wuytack F. (2006) A SERCA2 pump with an increased Ca2+ affinity can lead to severe cardiac hypertrophy, stress intolerance and reduced life span. J Mol Cell Cardiol;41:308-317.
8. Zhao W., Yuan Q., Qian J., Waggoner J.R., Pathak A., Chu G., Mitton B. et al. (2006) The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca2+-ATPase superinhibition and cardiac remodeling. Circulation;113:995-1004.
9. Haghighi K., Schmidt A.G., Hoit B.D., Brittsan A.G., Yatani A., Lester J.W., Zhai J., Kimura Y., Dorn G.W. II, MacLennan D.H., Kranias E.G. (2001) Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem;276:24145-24152.
10. Frank K.F., Bolck B., Brixius K., Kranias E.G., Schwinger R.H. (2002) Modulation of SERCA: implications for the failing human heart. Basic Res Cardiol;97 (Suppl. 1):I72-I78.
11. Schmitt J.P., Kamisago M., Asahi M., Li G.H., Ahmad F., Mende U., Kranias E.G., MacLennan D.H., Seidman J.G., Seidman C.E. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science;299:1410-1413.
12. Kadambi V.J., Ponniah S., Harrer J.M., Hoit B.D., Dorn G.W. II, Walsh R.A., Kranias E.G. (1996) Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest;97:533-539.
13. Nef H.M., Mollmann H., Skwara W., Bolck B., Schwinger R.H., Hamm C., Kostin S., Schaper J., Elsasser A. (2006) Reduced sarcoplasmic reticulum Ca2+ -ATPase activity and dephosphorylated phospholamban contribute to contractile dysfunction in human hibernating myocardium. Mol Cell Biochem;282:53-63.
14. Schmitt J.P., Ahmad F., Lorenz K., Hein L., Schulz S., Asahi M., Maclennan D.H., Seidman C.E., Seidman J.G., Lohse M.J. (2009) Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition. Circulation;119:436-444.
15. Haghighi K., Kolokathis F., Pater L., Lynch R.A., Asahi M., Gramolini A.O., Fan G.C., Tsiapras D., Hahn H.S., Adamopoulos S., Liggett S.B., Dorn G.W. II, MacLennan D.H., Kremastinos D.T. et al. (2003) Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest;111:869-876.
16. Fan G., Jiang Y.P., Lu Z., Martin D.W., Kelly D.J., Zuckerman J.M., Ballou L.M., Cohen I.S., Lin R.Z. (2005) A transgenic mouse model of heart failure using inducible Galpha q. J Biol Chem;280:40337-40346.
17. del Monte F., Harding S.E., Dec G.W., Gwathmey J.K., Hajjar R.J. (2002) Targeting phospholamban by gene transfer in human heart failure. Circulation;105:904-907.
18. Waggoner J.R., Kranias E.G. (2005) Role of phospholamban in the pathogenesis of heart failure. Heart Fail Clin;1:207-218.
19. Dieterle T., Meyer M., Gu Y., Belke D.D., Swanson E., Iwatate M., Hollander J., Peterson K.L., Ross J. Jr, Dillmann W.H. (2005) Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc Res;67:678-688.
20. Kaye D.M., Preovolos A., Marshall T., Byrne M., Hoshijima M., Hajjar R., Mariani J.A., Pepe S., Chien K.R., Power J.M. (2007) Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol;50:253-260.
21. Lockamy E.L., Cornea R.L., Karim C.B., Thomas D.D. (2011) Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure. Biochem Biophys Res Commun;408:388-392.
22. Zang X., Yu Z., Chu Y.H. (1998) Tight-binding streptavidin ligands from a cyclic peptide library. Bioorg Med Chem Lett;8:2327-2332.
23. Chang C.D., Meienhofer J. (1978) Solid-phase peptide synthesis using mild base cleavage of N alpha-fluorenylmethyloxycarbonylamino acids, exemplified by a synthesis of dihydrosomatostatin. Int J Pept Protein Res;11:246-249.
24. Vorherr T., Wrzosek A., Chiesi M., Carafoli E. (1993) Total synthesis and functional properties of the membrane-intrinsic protein phospholamban. Protein Sci;2:339-347.
25. Laemmli U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature;227:680-685.
26. Towbin H., Staehelin T., Gordon J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA;76:4350-4354.
27. Pollesello P., Annila A. (2002) Structure of the 1-36N-terminal fragment of human phospholamban phosphorylated at Ser-16 and Thr-17. Biophys J;83:484-490.
28. Parmley S.F., Smith G.P. (1988) Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene;73:305-318.
29. Sambrook J., Russell D. (2001) Purification of closed circular DNA by equilibrium centrifugation in CsCl-ethidium bromide gradients: continuous gradients. In: Sambrook J., Russell D., editors. Molecular Cloning A Laboratory Manual, 3rd edn. New York: Cold Spring Harbor Laboratory Press; p. 1.65-1.71.
30. Bratkovic T., Lunder M., Popovic T., Kreft S., Turk B., Strukelj B., Urleb U. (2005) Affinity selection to papain yields potent peptide inhibitors of cathepsins L, B, H, and K. Biochem Biophys Res Commun;332:897-903.
31. Ono K., Yano M., Ohkusa T., Kohno M., Hisaoka T., Tanigawa T., Kobayashi S., Matsuzaki M. (2000) Altered interaction of FKBP12.6 with ryanodine receptor as a cause of abnormal Ca(2+) release in heart failure. Cardiovasc Res;48:323-331.
32. Bradford M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem;72:248-254.
33. Fabiato A. (1988) Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. Methods Enzymol;157:378-417.
34. Yano M., Kohno M., Ohkusa T., Mochizuki M., Yamada J., Hisaoka T., Ono K., Tanigawa T., Kobayashi S., Matsuzaki M. (2000) Effect of milrinone on left ventricular relaxation and Ca(2+) uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol;279:H1898-H1905.
35. Wuthrich K. (1989) Protein structure determination in solution by nuclear magnetic resonance spectroscopy. Science;243:45-50.
36. Koradi R., Billeter M., Wüthrich K. (1996) MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph;14:51-55.
37. Bertucci C., Pistolozzi M., De Simone A. (2010) Circular dichroism in drug discovery and development: an abridged review. Anal Bioanal Chem;398:155-166.
38. Pollesello P., Annila A., Ovaska M. (1999) Structure of the 1-36 amino-terminal fragment of human phospholamban by nuclear magnetic resonance and modeling of the phospholamban pentamer. Biophys J;76:1784-1795.
39. He H., Meyer M., Martin J.L., McDonough P.M., Ho P., Lou X., Lew W.Y., Hilal-Dandan R., Dillmann W.H. (1999) Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility. Circulation;100:974-980.
40. Carr A.N., Schmidt A.G., Suzuki Y., del Monte F., Sato Y., Lanner C., Breeden K., Jing S.L., Allen P.B., Greengard P., Yatani A., Hoit B.D., Grupp I.L., Hajjar R.J. et al. (2002) Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol;22:4124-4135.
41. Zamoon J., Mascioni A., Thomas D.D., Veglia G. (2003) NMR solution structure and topological orientation of monomeric phospholamban in dodecylphosphocholine micelles. Biophys J;85:2589-2598.
42. Oxenoid K., Chou J.J. (2005) The structure of phospholamban pentamer reveals a channel-like architecture in membranes. Proc Natl Acad Sci USA;102:10870-10875.
43. Hutter M.C., Krebs J., Meiler J., Griesinger C., Carafoli E., Helms V. (2002) A structural model of the complex formed by phospholamban and the calcium pump of sarcoplasmic reticulum obtained by molecular mechanics. ChemBioChem;3:1200-1208.
44. Li J., Xiong Y., Bigelow D.J., Squier T.C. (2004) Phospholamban binds in a compact and ordered conformation to the Ca-ATPase. Biochemistry;43:455-463.
45. Toyoshima C., Asahi M., Sugita Y., Khanna R., Tsuda T., MacLennan D.H. (2003) Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase. Proc Natl Acad Sci USA;100:467-472.
46. James P., Inui M., Tada M., Chiesi M., Carafoli E. (1989) Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum. Nature;342:90-92.
47. Toyofuku T., Kurzydlowski K., Tada M., MacLennan D.H. (1994) Amino acids Lys-Asp-Asp-Lys-Pro-Val402 in the Ca(2+)-ATPase of cardiac sarcoplasmic reticulum are critical for functional association with phospholamban. J Biol Chem;269:22929-22932.
48. Rocchetti M., Alemanni M., Mostacciuolo G., Barassi P., Altomare C., Chisci R., Micheletti R., Ferrari P., Zaza A. (2008) Modulation of sarcoplasmic reticulum function by PST2744 [Istaroxime; (E, Z)-3-((2-Aminoethoxy)imino) Androstane-6, 17- dione Hydrochloride)] in a pressure-overload heart failure model. J Pharmacol Exp Ther;326:957-965.
49. Pystynen J. et al. (1999) Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors. International Patent Application No. WO 99/15523.
50. Pystynen J. et al. (1999) Use of phospholamban inhibitors for increasing coronary flow. International Patent Application No. WO 99/00132.
51. Haikala H. et al. (1999) A method for the prevention and treatment of stunned myocardium. International Patent Application No. WO 99/30696.
52. Pollesello P. et al. (2003) Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors). US Patent No. 6, 538, 022.
53. Pollesello P. et al. (2004) Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors). US Patent No. 6, 774, 103.